Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.

Papini, M; Cusano, F; Romanelli, M; Burlando, M; Stinco, G; Girolomoni, G; Peris, K; Potenza, C; Offidani, A; Bartezaghi, M; Aloisi, E; Costanzo, A

Papini, M; Cusano, F; Romanelli, M; Burlando, M; Stinco, G; Girolomoni, G; Peris, K; Potenza, C; Offidani, A; Bartezaghi, M; Aloisi, E; Costanzo, A.

Br J Dermatol ; 181(2): 413-414, 2019 08.

Article in En | MEDLINE | ID: mdl-31001812

Subject(s)

Antibodies, Monoclonal, Humanized/administration & dosage; HLA-C Antigens/blood; Psoriasis/drug therapy; Adult; Antibodies, Monoclonal, Humanized/adverse effects; Drug Administration Schedule; Female; HLA-C Antigens/immunology; Humans; Injections, Subcutaneous; Male; Middle Aged; Prospective Studies; Psoriasis/blood; Psoriasis/diagnosis; Psoriasis/immunology; Severity of Illness Index; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / HLA-C Antigens / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Diagnostic_studies / Observational_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Br J Dermatol Year: 2019 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google